XYXin Yang

Xin Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xin Yang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Chengli Mou

    School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, China

    1 shared publication
  • Gui-Lan Cai

    College of Pharmacy, Guizhou University of Traditional Chinese Medicine, South of Dongqing Road, Guiyang 550025, Guizhou Province, China

    1 shared publication
  • Jian Yang

    College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada

    1 shared publication
  • Meena Kishore Sakharkar

    Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada

    1 shared publication
  • Qing Liu

    College of Pharmacy, Guizhou University of Traditional Chinese Medicine, South of Dongqing Road, Guiyang 550025, Guizhou Province, China

    1 shared publication
  • Weiyi Tian

    Guizhou Key Laboratory of Microbial and Infectious Disease Prevention & Control, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Characterization of Nine Compounds Isolated from the Acid Hydrolysate of Lonicera fulvotomentosa Hsu et S. C. Cheng and Evaluation of Their In Vitro Activity towards HIV Protease

    by Xia Wang, Ying Wei, Wei-Yi Tian, Meena Kishore Sakharkar, Qing Liu, Xin Yang, Yan-Zi Zhou, Cheng-Li Mou, Gui-Lan Cai, Jian Yang

    In this study, we isolated nine compounds from the acid hydrolysate of the flower buds of Lonicera fulvotomentosa Hsu et S. C. Cheng and characterized their chemical structures using 1H-NMR, 13C-NMR, and electron ionization mass spectroscopy (EI-MS). These compounds were identified as β-sitosterol (1), 5,5′-dibutoxy-2,2′-bifuran (2), nonacosane-10-ol (3), ethyl (3β)-3,23-dihydroxyolean-12-en-28-oate (4), oleanolic acid (5), ethyl caffeate (6), caffeic acid (7), isovanillin (8), and hederagenin (9), with 4 as a new triterpene compound. Inhibitory activity against human immunodeficiency virus (HIV) protease was also evaluated for the compounds, and only ethyl caffeate, caffeic acid, and isovanillin (6, 7, and 8) exhibited inhibitory effects, with IC50 values of 1.0 μM, 1.5 μM, and 3.5 μM, respectively. Molecular docking with energy minimization and subsequent molecular dynamic (MD) simulation showed that ethyl caffeate and caffeic acid bound to the active site of HIV protease, while isovanillin drifted out from the active site and dissociated into bulk water during MD simulations, and most of the binding residues of HIV protease have been previously identified for HIV protease inhibitors. These results suggest that caffeic acid derivatives may possess inhibitory activities towards HIV protease other than previously reported inhibitory activities against HIV integrase, and thus ethyl caffeate and caffeic acid could be used as lead compounds in developing potential HIV protease inhibitors, and possibly even dual-function inhibitors against HIV.